166 related articles for article (PubMed ID: 32440111)
1. Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Ohar JA; Ozol-Godfrey A; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2020; 15():995-1004. PubMed ID: 32440111
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies.
Donohue JF; Ozol-Godfrey A; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2020; 15():745-754. PubMed ID: 32341641
[TBL] [Abstract][Full Text] [Related]
3. Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Tashkin DP; Ozol-Godfrey A; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2021; 16():945-955. PubMed ID: 33880019
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of glycopyrrolate/eFlow
Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
[TBL] [Abstract][Full Text] [Related]
5. Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies.
Hanania NA; Yohannes AM; Ozol-Godfrey A; Tocco M; Goodin T; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2021; 16():865-875. PubMed ID: 33833507
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
Ohar J; Tosiello R; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959
[TBL] [Abstract][Full Text] [Related]
7. Effect of background long-acting beta
Kerwin EM; Tosiello R; Price B; Sanjar S; Goodin T
Int J Chron Obstruct Pulmon Dis; 2018; 13():2917-2929. PubMed ID: 30275690
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.
Ohar JA; Bowling A; Goodin T; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():461-470. PubMed ID: 30863047
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety of glycopyrrolate/eFlow
Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
[TBL] [Abstract][Full Text] [Related]
10. Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD.
Putcha N; Ozol-Godfrey A; Sanjar S; Sharma S
Int J Chron Obstruct Pulmon Dis; 2021; 16():1061-1073. PubMed ID: 33907393
[TBL] [Abstract][Full Text] [Related]
11. Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies.
Kerwin EM; Murray L; Niu X; Dembek C
Int J Chron Obstruct Pulmon Dis; 2020; 15():2309-2318. PubMed ID: 33061349
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
[TBL] [Abstract][Full Text] [Related]
13. Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies.
Tashkin DP; Goodin T; Bowling A; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
Respir Res; 2019 Jul; 20(1):135. PubMed ID: 31266489
[TBL] [Abstract][Full Text] [Related]
14. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
16. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
[TBL] [Abstract][Full Text] [Related]
18. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
20. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]